Detailed Narrative
Robust Q3 FY25 Performance Driven by Volume and Strategic Acquisitions
Thyrocare Technologies reported a strong Q3 FY25, with consolidated revenue growing 23% year-on-year to INR166 crores. This growth was underpinned by a 15% increase in samples processed, reaching 5.9 million, and a 13% rise in patients served, totaling 3.9 million. The company also saw a 14% YoY increase in total tests conducted, amounting to 39 million. Consolidated normalized EBITDA margin stood at 30%, with normalized EBITDA growing 42% YoY, and PAT increasing 30% YoY.
Franchisee and Partnership Businesses Fuel Growth
Both key business segments demonstrated significant expansion. The franchisee business recorded a 24% year-on-year revenue growth, driven by 19% organic and 5% inorganic contributions. The partnership business also grew 23% year-on-year, with the API PharmEasy Diagnostic business showing a 19% YoY growth. Management highlighted that higher-tier franchisees (Diamond to Silver) grew 25% in volume, while other categories (Bronze and others) grew 9% in volume, indicating success in their slab-based pricing model.
Strategic Expansion and Unwavering Commitment to Quality
Thyrocare continues to expand its footprint through strategic acquisitions, including Polo Labs (mentioned as July 2024 in transcript, likely 2023) for North India and Vimta Labs (mentioned as October 2024, likely 2023) for South India. The company has also enhanced its service offerings, such as ECG at Home services now available in over 1,000 pin codes. A major achievement was becoming India's first and only 100% NABL accredited national laboratory chain, underscoring its dedication to world-class diagnostic standards.
Vimta Labs Acquisition: Short-term Loss, Clear Path to Profitability
The acquisition of Vimta Labs, consolidated for 2.5 months in Q3, contributed INR4-4.5 crores to revenue but resulted in an EBITDA loss of INR1.4 crores for the quarter. Management expects the integration to stabilize within 3-6 months, with a projected quarterly revenue run rate of INR3-4 crores for the next four quarters. The goal is to bring Vimta Labs to breakeven at the EBITDA level within the next half-year, after streamlining non-core businesses and consolidating operations.
Impact of ESOP and Depreciation Charges on Financials
The company reported a non-cash ESOP charge of approximately INR7 crores in Q3, related to a new INR47 crore API ESOP pool for senior management, which will be amortized over 6 years. Additionally, a one-off📎 depreciation hit of INR4.75 crores was recorded due to a revision in the estimated life expectancy of assets from 12-14 years to 7 years. These charges, while impacting reported profitability, are non-cash and do not affect the company's cash flow.
Stabilizing Pricing Environment and Focus on Value Proposition
Management noted a softening in the pricing environment over the past 2-3 quarters, indicating a shift away from aggressive price competition towards a focus on service and quality. While India's diagnostic prices remain globally low, the company believes a 'rationality' has set in, and this trend is expected to continue. Thyrocare's core value proposition remains providing affordable, high-quality, and timely diagnostic services to its B2B partners and patients.
Nascent International Expansion in Tanzania
Thyrocare's international foray into Tanzania, which commenced operations in March 2024, is still in its early stages. The business generated approximately INR30-35 lakhs in revenue during Q3 FY25. The company has successfully partnered with over 100 healthcare facilities in Dar es Salaam, and management is focused on gradually increasing its partnership base and wallet share from existing partners as the operations mature.